Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Comment by pabalooon Apr 08, 2020 7:45pm

86 Views

Post# 30892334

RE:Are They Inking a Deal or Perhaps Trulance?

Swapper I would love to see 12 million in cash and no debt on the balance sheet in December. I'm guessing more so closer to March but your statement is correct that by year end we should have a buck a share in cash. The way the market values us presently is exactly that, cash almost no value for any of our products! Trulance is the game changer here, we need an agreement that is fair I'm hoping for a cash buyout of 15 plus million. That should move the stock up!

Bullboard Posts

Canadian psychedelic stock to supply MDMA to Yale